Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.

Chakrabarti, Gaurab

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. [electronic resource] - Scientific reports Nov 2015 - 17066 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

2045-2322

10.1038/srep17066 doi


Animals
Autophagy--drug effects
Catalase--genetics
Cell Line, Tumor
Cell Survival--drug effects
DNA Breaks, Double-Stranded--drug effects
DNA Glycosylases--antagonists & inhibitors
DNA Repair--drug effects
DNA-Binding Proteins--antagonists & inhibitors
Dicumarol--pharmacology
Female
Humans
Hydroxylamines--pharmacology
Mice
Mice, Nude
NAD(P)H Dehydrogenase (Quinone)--antagonists & inhibitors
Naphthoquinones--pharmacology
Pancreatic Neoplasms--drug therapy
Poly(ADP-ribose) Polymerases--metabolism
Reactive Oxygen Species--metabolism
Transplantation, Heterologous
X-ray Repair Cross Complementing Protein 1